K-CONNECT PLATFORM
Empowering the Potential of
ctDNA-MRD
Empowering
Cancer Care
With Multi-Dimensional Genomics
& Artificial Intelligence
Gene Solutions expands into the U.S.
Strategic collaboration
with Pangea Laboratory
K-CONNECT PLATFORM
Empowering the Potential of
ctDNA-MRD
Empowering
Cancer Care
With Multi-Dimensional Genomics
& Artificial Intelligence
Gene Solutions expands into the U.S.
Strategic collaboration
with Pangea Laboratory
K-CONNECT PLATFORM
Empowering the Potential of
ctDNA-MRD
The Unique Combination of Multi-dimensional Genomics & AI in Cancer Care
Detection
Early cancer detection by screening for tumor DNA in the blood (ctDNA).
Profiling
Next-generation sequencing (NGS) tumor profiling for precision therapies.
Monitoring
Personalized ctDNA monitoring for recurrence risk and treatment responses.
Innovation
Discovery of multi-omics targets for new drug insights and novel therapies development.
News & Updates
Get the latest news and updates of our company and medical field.
SPOT-MAS Launches in Taiwan: AI-Powered Multi-Cancer Early Detection Ushers in a New Era of Precision Medicine
Precision medicine is entering a new era, driven by breakthroughs in genetic technology and Artificial Intelligence (AI). Multi-Cancer Early Detection (MCED) has become a global trend, and Taiwan joins this movement
MCED and Traditional Screening: A Comprehensive, Complementary Strategy
Traditional cancer screenings such as mammography and colonoscopy remain essential tools that have reduced cancer deaths for decades. Yet, these tests only cover a few cancer types and depend on
World Cancer Day: Genomics & AI Blood Test Detects Cancer Before Symptoms Appear in India
PRESS RELEASE As late-stage cancer diagnosis continues to drive mortality and financial distress in India, Gene Solutions and Global Cancer Care highlight the role of early detection and patient navigation
Gene Solutions and Pangea Laboratory Establish Strategic Collaboration to Validate Laboratory Developed ctDNA Tests for Precision Screening and Cancer Care in the U.S.
IRVINE, Calif. — January 21, 2026 — Gene Solutions, a global biotechnology company, and Pangea Laboratory, a CLIA-certified, CAP-accredited Next Generation Sequencing (NGS) leader in validation platforms for Laboratory Developed
The MCED Test experience
The experience with multi-cancer early detection tests offers a closer look at how this approach may be shaping aspects of preventive healthcare. In the context of this MCED article, we
K-TRACK Performance Validated in JTO Clinical and Research Reports: A Direct Comparison of Tumor‑Informed and Tumor‑Naïve ctDNA‑MRD Testing in Early‑Stage NSCLC
Gene Solutions is pleased to announce the publication of our latest research in JTO Clinical and Research Reports, evaluating the K-TRACK portfolio entitled: “Direct Comparison of Tumor-Informed and Tumor-Naïve ctDNA
Two Best Poster Awards at ESMO Asia 2025
This year at ESMO Asia 2025 in Singapore, the R&D team from Gene Solutions was honored with two Best Poster Awards — recognition that reflects not only scientific excellence, but
Bridging Genomic Insights: AI‑Powered Liquid Biopsy and Multi‑Omics at ESMO Asia Congress 2025
At ESMO Asia Congress 2025 (December 5–7), Gene Solutions’ Industry Satellite Symposium brought together leading voices from across the region to examine how AI-driven liquid biopsy and multi‑omics are reshaping
Gene Solutions at POGS 2025: Advancing Precision & Preventive Care
PUNE, INDIA — December 2025 — Gene Solutions was proud to participate in the 34th Annual Conference of the Pune Obstetrics and Gynecology Society (POGS) and welcomed more than 310
Gene Solutions Announces Publication in Cancer Medicine Showcasing Integrated Tumor DNA-RNA Profiling with Longitudinal ctDNA Monitoring
Gene Solutions today announced the publication of a peer-reviewed study using the K-4CARE assay in Cancer Medicine entitled “Tumor Genomic and Transcriptomic Analysis Integrated with Liquid Biopsy ctDNA Monitoring: Analytical
Symposium Summary: Expanding Horizons in NIPT – From Aneuploidy to Single-Gene Disorders
As part of our ongoing education series for OBGYNs on the evolution of Non-Invasive Prenatal Testing (NIPT), we successfully hosted the symposium “Expanding Horizons in NIPT – From Aneuploidy to
Gene Solutions to Showcase Latest Data on Multi-omics and AI for Precision Oncology at ESMO Asia Congress 2025
Gene Solutions will present latest advancements in multi-omics integration and AI-powered analytics for precision oncology at the European Society for Medical Oncology (ESMO) Asia Congress 2025, taking place December 5–7
SPOT-MAS Launches in Taiwan: AI-Powered Multi-Cancer Early Detection Ushers in a New Era of Precision Medicine
Precision medicine is entering a new era, driven by breakthroughs in genetic technology and Artificial Intelligence (AI). Multi-Cancer Early Detection (MCED) has become a global trend, and Taiwan joins this movement
MCED and Traditional Screening: A Comprehensive, Complementary Strategy
Traditional cancer screenings such as mammography and colonoscopy remain essential tools that have reduced cancer deaths for decades. Yet, these tests only cover a few cancer types and depend on
World Cancer Day: Genomics & AI Blood Test Detects Cancer Before Symptoms Appear in India
PRESS RELEASE As late-stage cancer diagnosis continues to drive mortality and financial distress in India, Gene Solutions and Global Cancer Care highlight the role of early detection and patient navigation
Gene Solutions and Pangea Laboratory Establish Strategic Collaboration to Validate Laboratory Developed ctDNA Tests for Precision Screening and Cancer Care in the U.S.
IRVINE, Calif. — January 21, 2026 — Gene Solutions, a global biotechnology company, and Pangea Laboratory, a CLIA-certified, CAP-accredited Next Generation Sequencing (NGS) leader in validation platforms for Laboratory Developed
The MCED Test experience
The experience with multi-cancer early detection tests offers a closer look at how this approach may be shaping aspects of preventive healthcare. In the context of this MCED article, we
K-TRACK Performance Validated in JTO Clinical and Research Reports: A Direct Comparison of Tumor‑Informed and Tumor‑Naïve ctDNA‑MRD Testing in Early‑Stage NSCLC
Gene Solutions is pleased to announce the publication of our latest research in JTO Clinical and Research Reports, evaluating the K-TRACK portfolio entitled: “Direct Comparison of Tumor-Informed and Tumor-Naïve ctDNA
Two Best Poster Awards at ESMO Asia 2025
This year at ESMO Asia 2025 in Singapore, the R&D team from Gene Solutions was honored with two Best Poster Awards — recognition that reflects not only scientific excellence, but
Bridging Genomic Insights: AI‑Powered Liquid Biopsy and Multi‑Omics at ESMO Asia Congress 2025
At ESMO Asia Congress 2025 (December 5–7), Gene Solutions’ Industry Satellite Symposium brought together leading voices from across the region to examine how AI-driven liquid biopsy and multi‑omics are reshaping
Gene Solutions at POGS 2025: Advancing Precision & Preventive Care
PUNE, INDIA — December 2025 — Gene Solutions was proud to participate in the 34th Annual Conference of the Pune Obstetrics and Gynecology Society (POGS) and welcomed more than 310
Gene Solutions Announces Publication in Cancer Medicine Showcasing Integrated Tumor DNA-RNA Profiling with Longitudinal ctDNA Monitoring
Gene Solutions today announced the publication of a peer-reviewed study using the K-4CARE assay in Cancer Medicine entitled “Tumor Genomic and Transcriptomic Analysis Integrated with Liquid Biopsy ctDNA Monitoring: Analytical
Symposium Summary: Expanding Horizons in NIPT – From Aneuploidy to Single-Gene Disorders
As part of our ongoing education series for OBGYNs on the evolution of Non-Invasive Prenatal Testing (NIPT), we successfully hosted the symposium “Expanding Horizons in NIPT – From Aneuploidy to
Gene Solutions to Showcase Latest Data on Multi-omics and AI for Precision Oncology at ESMO Asia Congress 2025
Gene Solutions will present latest advancements in multi-omics integration and AI-powered analytics for precision oncology at the European Society for Medical Oncology (ESMO) Asia Congress 2025, taking place December 5–7
SPOT-MAS Launches in Taiwan: AI-Powered Multi-Cancer Early Detection Ushers in a New Era of Precision Medicine
Precision medicine is entering a new era, driven by breakthroughs in genetic technology and Artificial Intelligence (AI). Multi-Cancer Early Detection (MCED) has become a global trend, and Taiwan joins this movement
MCED and Traditional Screening: A Comprehensive, Complementary Strategy
Traditional cancer screenings such as mammography and colonoscopy remain essential tools that have reduced cancer deaths for decades. Yet, these tests only cover a few cancer types and depend on
Gene Solutions at POGS 2025: Advancing Precision & Preventive Care
PUNE, INDIA — December 2025 — Gene Solutions was proud to participate in the 34th Annual Conference of the Pune Obstetrics and Gynecology Society (POGS) and welcomed more than 310
Gene Solutions Announces Publication in Cancer Medicine Showcasing Integrated Tumor DNA-RNA Profiling with Longitudinal ctDNA Monitoring
Gene Solutions today announced the publication of a peer-reviewed study using the K-4CARE assay in Cancer Medicine entitled “Tumor Genomic and Transcriptomic Analysis Integrated with Liquid Biopsy ctDNA Monitoring: Analytical
Symposium Summary: Expanding Horizons in NIPT – From Aneuploidy to Single-Gene Disorders
As part of our ongoing education series for OBGYNs on the evolution of Non-Invasive Prenatal Testing (NIPT), we successfully hosted the symposium “Expanding Horizons in NIPT – From Aneuploidy to
Gene Solutions to Showcase Latest Data on Multi-omics and AI for Precision Oncology at ESMO Asia Congress 2025
Gene Solutions will present latest advancements in multi-omics integration and AI-powered analytics for precision oncology at the European Society for Medical Oncology (ESMO) Asia Congress 2025, taking place December 5–7
SPOT-MAS Launches in Taiwan: AI-Powered Multi-Cancer Early Detection Ushers in a New Era of Precision Medicine
Precision medicine is entering a new era, driven by breakthroughs in genetic technology and Artificial Intelligence (AI). Multi-Cancer Early Detection (MCED) has become a global trend, and Taiwan joins this movement
MCED and Traditional Screening: A Comprehensive, Complementary Strategy
Traditional cancer screenings such as mammography and colonoscopy remain essential tools that have reduced cancer deaths for decades. Yet, these tests only cover a few cancer types and depend on
World Cancer Day: Genomics & AI Blood Test Detects Cancer Before Symptoms Appear in India
PRESS RELEASE As late-stage cancer diagnosis continues to drive mortality and financial distress in India, Gene Solutions and Global Cancer Care highlight the role of early detection and patient navigation
Gene Solutions and Pangea Laboratory Establish Strategic Collaboration to Validate Laboratory Developed ctDNA Tests for Precision Screening and Cancer Care in the U.S.
IRVINE, Calif. — January 21, 2026 — Gene Solutions, a global biotechnology company, and Pangea Laboratory, a CLIA-certified, CAP-accredited Next Generation Sequencing (NGS) leader in validation platforms for Laboratory Developed
The MCED Test experience
The experience with multi-cancer early detection tests offers a closer look at how this approach may be shaping aspects of preventive healthcare. In the context of this MCED article, we
K-TRACK Performance Validated in JTO Clinical and Research Reports: A Direct Comparison of Tumor‑Informed and Tumor‑Naïve ctDNA‑MRD Testing in Early‑Stage NSCLC
Gene Solutions is pleased to announce the publication of our latest research in JTO Clinical and Research Reports, evaluating the K-TRACK portfolio entitled: “Direct Comparison of Tumor-Informed and Tumor-Naïve ctDNA
Two Best Poster Awards at ESMO Asia 2025
This year at ESMO Asia 2025 in Singapore, the R&D team from Gene Solutions was honored with two Best Poster Awards — recognition that reflects not only scientific excellence, but
Bridging Genomic Insights: AI‑Powered Liquid Biopsy and Multi‑Omics at ESMO Asia Congress 2025
At ESMO Asia Congress 2025 (December 5–7), Gene Solutions’ Industry Satellite Symposium brought together leading voices from across the region to examine how AI-driven liquid biopsy and multi‑omics are reshaping
Gene Solutions at POGS 2025: Advancing Precision & Preventive Care
PUNE, INDIA — December 2025 — Gene Solutions was proud to participate in the 34th Annual Conference of the Pune Obstetrics and Gynecology Society (POGS) and welcomed more than 310
Gene Solutions Announces Publication in Cancer Medicine Showcasing Integrated Tumor DNA-RNA Profiling with Longitudinal ctDNA Monitoring
Gene Solutions today announced the publication of a peer-reviewed study using the K-4CARE assay in Cancer Medicine entitled “Tumor Genomic and Transcriptomic Analysis Integrated with Liquid Biopsy ctDNA Monitoring: Analytical
Symposium Summary: Expanding Horizons in NIPT – From Aneuploidy to Single-Gene Disorders
As part of our ongoing education series for OBGYNs on the evolution of Non-Invasive Prenatal Testing (NIPT), we successfully hosted the symposium “Expanding Horizons in NIPT – From Aneuploidy to
Gene Solutions to Showcase Latest Data on Multi-omics and AI for Precision Oncology at ESMO Asia Congress 2025
Gene Solutions will present latest advancements in multi-omics integration and AI-powered analytics for precision oncology at the European Society for Medical Oncology (ESMO) Asia Congress 2025, taking place December 5–7
SPOT-MAS Launches in Taiwan: AI-Powered Multi-Cancer Early Detection Ushers in a New Era of Precision Medicine
Precision medicine is entering a new era, driven by breakthroughs in genetic technology and Artificial Intelligence (AI). Multi-Cancer Early Detection (MCED) has become a global trend, and Taiwan joins this movement
MCED and Traditional Screening: A Comprehensive, Complementary Strategy
Traditional cancer screenings such as mammography and colonoscopy remain essential tools that have reduced cancer deaths for decades. Yet, these tests only cover a few cancer types and depend on
World Cancer Day: Genomics & AI Blood Test Detects Cancer Before Symptoms Appear in India
PRESS RELEASE As late-stage cancer diagnosis continues to drive mortality and financial distress in India, Gene Solutions and Global Cancer Care highlight the role of early detection and patient navigation
Gene Solutions and Pangea Laboratory Establish Strategic Collaboration to Validate Laboratory Developed ctDNA Tests for Precision Screening and Cancer Care in the U.S.
IRVINE, Calif. — January 21, 2026 — Gene Solutions, a global biotechnology company, and Pangea Laboratory, a CLIA-certified, CAP-accredited Next Generation Sequencing (NGS) leader in validation platforms for Laboratory Developed
The MCED Test experience
The experience with multi-cancer early detection tests offers a closer look at how this approach may be shaping aspects of preventive healthcare. In the context of this MCED article, we
K-TRACK Performance Validated in JTO Clinical and Research Reports: A Direct Comparison of Tumor‑Informed and Tumor‑Naïve ctDNA‑MRD Testing in Early‑Stage NSCLC
Gene Solutions is pleased to announce the publication of our latest research in JTO Clinical and Research Reports, evaluating the K-TRACK portfolio entitled: “Direct Comparison of Tumor-Informed and Tumor-Naïve ctDNA
Two Best Poster Awards at ESMO Asia 2025
This year at ESMO Asia 2025 in Singapore, the R&D team from Gene Solutions was honored with two Best Poster Awards — recognition that reflects not only scientific excellence, but
Bridging Genomic Insights: AI‑Powered Liquid Biopsy and Multi‑Omics at ESMO Asia Congress 2025
At ESMO Asia Congress 2025 (December 5–7), Gene Solutions’ Industry Satellite Symposium brought together leading voices from across the region to examine how AI-driven liquid biopsy and multi‑omics are reshaping
Gene Solutions at POGS 2025: Advancing Precision & Preventive Care
PUNE, INDIA — December 2025 — Gene Solutions was proud to participate in the 34th Annual Conference of the Pune Obstetrics and Gynecology Society (POGS) and welcomed more than 310
Gene Solutions Announces Publication in Cancer Medicine Showcasing Integrated Tumor DNA-RNA Profiling with Longitudinal ctDNA Monitoring
Gene Solutions today announced the publication of a peer-reviewed study using the K-4CARE assay in Cancer Medicine entitled “Tumor Genomic and Transcriptomic Analysis Integrated with Liquid Biopsy ctDNA Monitoring: Analytical
Symposium Summary: Expanding Horizons in NIPT – From Aneuploidy to Single-Gene Disorders
As part of our ongoing education series for OBGYNs on the evolution of Non-Invasive Prenatal Testing (NIPT), we successfully hosted the symposium “Expanding Horizons in NIPT – From Aneuploidy to
Gene Solutions to Showcase Latest Data on Multi-omics and AI for Precision Oncology at ESMO Asia Congress 2025
Gene Solutions will present latest advancements in multi-omics integration and AI-powered analytics for precision oncology at the European Society for Medical Oncology (ESMO) Asia Congress 2025, taking place December 5–7
SPOT-MAS Launches in Taiwan: AI-Powered Multi-Cancer Early Detection Ushers in a New Era of Precision Medicine
Precision medicine is entering a new era, driven by breakthroughs in genetic technology and Artificial Intelligence (AI). Multi-Cancer Early Detection (MCED) has become a global trend, and Taiwan joins this movement
MCED and Traditional Screening: A Comprehensive, Complementary Strategy
Traditional cancer screenings such as mammography and colonoscopy remain essential tools that have reduced cancer deaths for decades. Yet, these tests only cover a few cancer types and depend on
CAP-Accredited Laboratory
Gene Solutions uniquely operates 2 CAP-accredited laboratories specializing in next-generation sequencing (NGS), within a network of 7 NGS laboratories in Asia.
Gene Solutions joins an esteemed group of laboratories worldwide. This rigorous process ensures that we not only meet but exceed the highest standards of care, ultimately delivering the best possible outcomes for our patients.
Gene Solutions Genomics Singapore Laboratory CAP#9709518
